Sterling Investment Counsel’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.71M Buy
13,344
+265
+2% +$31K 0.4% 42
2026
Q1
$1.57M Buy
13,079
+181
+1% +$20.9K 0.44% 41
2025
Q4
$1.34M Buy
12,898
+3,636
+39% +$341K 0.38% 51
2025
Q3
$777K Buy
9,262
+3,276
+55% +$270K 0.25% 66
2025
Q2
$474K Sell
5,986
-5,184
-46% -$412K 0.28% 59
2025
Q1
$1M Buy
11,170
+5,572
+100% +$520K 0.34% 54
2024
Q4
$557K Sell
5,598
-4,966
-47% -$512K 0.37% 47
2024
Q3
$1.2M Buy
10,564
+4,495
+74% +$534K 0.43% 47
2024
Q2
$751K Sell
6,069
-369
-6% -$47.5K 0.3% 57
2024
Q1
$850K Buy
6,438
+32
+0.5% +$3.94K 0.39% 50
2023
Q4
$698K Sell
6,406
-657
-9% -$68.2K 0.36% 51
2023
Q3
$727K Hold
7,063
0.42% 48
2023
Q2
$815K Sell
7,063
-2,004
-22% -$228K 0.44% 42
2023
Q1
$965K Sell
9,067
-1,023
-10% -$110K 0.57% 30
2022
Q4
$1.12M Hold
10,090
0.69% 27
2022
Q3
$869K Sell
10,090
-276
-3% -$24.6K 0.63% 29
2022
Q2
$944K Sell
10,366
-292
-3% -$25.9K 0.72% 23
2022
Q1
$875K Buy
10,658
+2,357
+28% +$186K 0.59% 27
2021
Q4
$636K Buy
+8,301
New +$661K 0.43% 45

Other funds holding MRK

Sterling Investment Counsel's MRK Position: Q2 2026 in Review

Sterling Investment Counsel increased its Merck (MRK) stake by 2% in Q2 2026, buying an estimated $31K and bringing the position to 13,344 shares worth $1.71M. The position accounts for 0.4% of the portfolio, ranked #42.

Sterling Investment Counsel first reported a position in MRK in Q4 2021 and has held it in 19 quarters since. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Sterling Investment Counsel held 13,344 shares of Merck worth $1.71M as of Q2 2026.
  • Sterling Investment Counsel bought 265 Merck shares in Q2 2026, an estimated $31K.
  • Merck made up 0.4% of Sterling Investment Counsel's portfolio in Q2 2026, its #42 holding.
  • Sterling Investment Counsel first reported a position in Merck in Q4 2021 and has held it in 19 quarters since.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Sterling Investment Counsel's 13F filing for Q2 2026, filed 20 Jul 2026.